Colorectal cancer metastatic
Not recruitingStudy comparing trifluridine/tipiracil with bevacizumab versus capecitabine with bevacizumab as first-line treatment for patients with metastatic colorectal cancer who cannot receive intensive therapy
Study comparing trifluridine/tipiracil with bevacizumab versus capecitabine with bevacizumab as first-line treatment for patients with metastatic colorectal cancer who cannot receive intensive therapy
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabCapecitabine+2
Denmark- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Institut De Recherches Internationales Servier IRIS



